Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

Author： Vallet Sonia Witzens-Harig Mathias Jaeger Dirk Podar Klaus

ISSN： 1465-6566

Source： Expert Opinion on Pharmacotherapy, Vol.13, Iss.4, 2012-03, pp. : 473-494

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Update on immunomodulatory drugs (IMiDs) in hematologic and solid malignancies

By Schafer Peter H

Expert Opinion on Pharmacotherapy, Vol. 13, Iss. 10, 2012-07 ,pp. : 1541-1542

Informa Healthcare

Access to resources Recommend Favorite

Immunomodulatory Drugs (IMiDs) in Multiple Myeloma

Current Cancer Drug Targets, Vol. 17, Iss. 9, 2017-10 ,pp. : 846-857

Bentham Science Publishers

Access to resources Recommend Favorite

Immunomodulatory Drugs (IMiDs™): A New Treatment Option for Myelodysplastic Syndromes

Current Pharmaceutical Biotechnology, Vol. 7, Iss. 5, 2006-10 ,pp. : 339-342

Bentham Science Publishers

Access to resources Recommend Favorite

Thalidomide Derived Immunomodulatory Drugs (IMiDs) as Potential Therapeutic Agents

Current Drug Targets - Immune, Endocrine & Metabolic Disorders, Vol. 3, Iss. 3, 2003-09 ,pp. : 181-186

Bentham Science Publishers

Access to resources Recommend Favorite

Entinostat for treatment of solid tumors and hematologic malignancies

By Knipstein Jeffrey Gore Lia

Expert Opinion on Investigational Drugs, Vol. 20, Iss. 10, 2011-10 ,pp. : 1455-1467

Informa Healthcare

Access to resources Recommend Favorite